KPV is a tripeptide: three amino acids, lysine, proline and valine. It matches the last three residues (11 to 13) of alpha-melanocyte-stimulating hormone (alpha-MSH), a natural hormone made from a larger precursor protein. Researchers began studying KPV to find out whether this small piece keeps some of alpha-MSH’s anti-inflammatory activity. Almost all the published work is in cells and animals.
For laboratory research use only. Not for human or animal consumption. Not intended to diagnose, treat, cure or prevent any disease.
Structure
| Property | Value |
|---|---|
| Sequence | Lys-Pro-Val (KPV) |
| Length | 3 amino acids (tripeptide) |
| Molecular formula | C₁₆H₃₀N₄O₄ |
| Molecular weight | ~342.4 g/mol |
| Origin | Residues 11–13 of alpha-MSH |
| Other names | Lysyl-prolyl-valine, alpha-MSH (11-13) |
In alpha-MSH itself, the final valine carries an amide group. KPV as usually studied and supplied is the free peptide (or its acetate salt). Papers do not always say which form they used, so check the methods section.
What research has looked at
Most KPV research is in cell cultures and mouse models, much of it from gut-inflammation groups. The main areas are:
- Gut inflammation models. In 2008, two groups reported that KPV reduced inflammation in mouse models of colitis. One study found that KPV enters gut-lining and immune cells through PepT1, a transporter for small peptides. It also found that KPV reduced activity of NF-κB, a key inflammation signaling pathway.
- Mechanism. KPV comes from alpha-MSH, which acts on melanocortin receptors. However, one of the 2008 mouse studies found that KPV’s effects were at least partly independent of the MC1R receptor. How KPV works is still not settled.
- Delivery systems. Much of the newer work packages KPV in nanoparticles, hydrogels and other carriers. The aim is to deliver it to the colon or the skin and study it there.
- Skin and other cell models. Studies in skin cells exposed to fine dust, and 2026 cell studies of fat-cell formation, liver-cell fat buildup and immune cells involved in artery plaque.
Limits of the evidence
- All published KPV data are preclinical (cell and animal models). No human exposure data for KPV have been published. We found no KPV studies registered on ClinicalTrials.gov as of November 2026.
- Many recent studies test KPV inside a delivery system. Those results may not apply to the free peptide.
- The mechanism is unresolved, and it may differ between models.
- KPV is not approved by the FDA for any use.
- KPV is not named on the World Anti-Doping Agency’s 2026 prohibited list. The list has a catch-all class (S0) for substances not approved for human use. We could not find an official ruling on whether that class covers KPV.
Researchers should read the primary literature directly. PubMed lists the original studies under “KPV” and “Lys-Pro-Val”.
Forms OmegAmino supplies
| Form | Amount |
|---|---|
| Lyophilized powder | 10 mg vial |
| In blends | Mutant (with TB-500 and BPC-157), Mammoth Hibernation (with DSIP and Selank) |
Every batch is third-party tested for identity and purity. You can look up the Certificate of Analysis for the KPV we supply at omegamino-coas.com. Read more about how we test.
Storage
Store lyophilized peptide sealed and refrigerated, kept cool, dark and away from moisture. We don’t recommend home freezers: their defrost cycles warm and cool the contents repeatedly, which can damage peptides. Once reconstituted, keep the solution refrigerated and use it within the period your protocol specifies.
Related research
- BPC-157, studied in gut models and paired with KPV in the Mutant blend
- TB-500
- GHK-Cu
- All research overviews
Researchers with an approved account can order from the shop.
